Brief: MorphoSys Expects Topline Data From Phase 3 Study Of Pelabresib In Myelofibrosis

Morphosys AG

09/01/2023 06:05

Jan 9 (Reuters) - MORPHOSYS AG  MORG.DE :
    * MORPHOSYS EXPECTS TOPLINE DATA FROM PHASE 3 STUDY OF
PELABRESIB
IN MYELOFIBROSIS IN EARLY 2024
    * COMPANY PREVIOUSLY COMMUNICATED THAT THESE DATA WERE
EXPECTED IN
FIRST HALF OF 2024
    * JEAN-PAUL KRESS, M.D., CHIEF EXECUTIVE OFFICER OF
MORPHOSYS,
WILL PROVIDE FURTHER UPDATES ON PELABRESIB PROGRAM AND REST OF
COMPANY'S ONCOLOGY PIPELINE AT 41ST ANNUAL J.P. MORGAN
HEALTHCARE CONFERENCE ON WEDNESDAY, JANUARY 11, 2023

Source text for Eikon:  ID:nEQ6Qb1Nxa 
Further company coverage:  MORG.DE 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))